Inconsistent ALS Trial Analytics Increase False Positive Risk

The Statistical Fragility of Functional Assessment in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis remains a rapidly progressive and fatal neurodegenerative condition characterized by significant clinical heterogeneity [1]. Despite decades of research into pathogenic targets and genetic variants, the translation of therapies into the clinic has been historically slow [2, 1]. Clinicians rely heavily on standardized disability rating scales to monitor disease progression and evaluate the efficacy of interventions in the trial setting [3, 4]. However, the inherent variability in how individual patients progress makes it difficult to distinguish true treatment effects from natural disease fluctuations [4]. While cognitive and behavioral impairments further complicate the clinical picture and increase the overall caregiver burden, the functional rating scale remains the primary metric for determining trial success [5, 6]. A new analysis of 45 randomized clinical trials involving 7,338 patients now suggests that 38.9% of statistical methods used to analyze these scales are at risk of increasing false-positive rates, potentially leading to the advancement of ineffective treatments [7].

Mapping Methodological Diversity Across 45 Randomized Trials

To investigate the impact of analytical variability on clinical outcomes, the researchers conducted a systematic search of PubMed and Embase to identify randomized, placebo-controlled clinical trials that utilized the revised ALS functional rating scale (ALSFRS-R) as their primary end point. The inclusion criteria were strictly defined to ensure a robust data set, requiring each trial to have at least 20 randomly assigned patients and a follow-up period of 12 weeks or longer. Through this process, the authors extracted detailed data on the specific statistical analysis approaches employed by each study, as well as the strategies used for handling missing data, which is a common challenge in neurodegenerative disease research due to high patient attrition. The final analysis encompassed 45 randomized clinical trials representing a total sample size of 7,338 patients, providing a comprehensive overview of the current landscape in amyotrophic lateral sclerosis research. The researchers mapped the observed variability in statistical methods to the specific research questions each trial intended to address, uncovering a fragmented methodological environment. Specifically, the study identified 39 distinct statistical methods used across these trials. These approaches consisted of a mixture of longitudinal techniques (methods that analyze data collected over multiple time points to track a patient's disease trajectory) and cross-sectional techniques (methods that evaluate data from only a single point in time, such as the final visit). This high degree of methodological diversity suggests a lack of standardization in how clinicians and researchers interpret functional decline in patients, which can lead to conflicting interpretations of the same clinical data.

Quantifying the Impact of Analytical Choice on Clinical Conclusions

The researchers explored how disability rating scales have been analyzed in completed amyotrophic lateral sclerosis clinical trials to understand the real-world implications of methodological choices. To achieve this, they conducted a simulation study using the Ceftriaxone trial data set to model a realistic trial scenario. This allowed the authors to assess both validity (the false-positive rate, or the likelihood of finding an effect that does not exist) and precision (the statistical power to detect a true treatment effect when one is present). By using a known data set as a baseline, the study could isolate how different analytical frameworks altered the perceived efficacy of a drug regardless of the underlying biological response. A significant finding was that 55.6% of the 45 trials reviewed did not use all available longitudinal measurements of the revised ALS functional rating scale (ALSFRS-R). In clinical research, longitudinal data involves repeated observations of the same patient over time, providing a more complete picture of disease progression than a single snapshot. The researchers noted that this failure to incorporate all available time points resulted in the suboptimal utilization of patient data and reduced statistical precision, which refers to the degree of certainty or consistency in the results. For the practicing clinician, this means that more than half of these trials may have overlooked critical information about how patients were actually responding to therapy over the duration of the study, potentially masking the true clinical utility of the intervention. The impact of these analytical choices was most evident when the researchers applied the 39 identified statistical methods to the same trial data set. This exercise revealed that the choice of model alone could swing the results dramatically. Specifically, the estimated treatment effect sizes ranged from a negative 1.33 to a positive 2.33 standard deviation difference. Such a wide variance suggests that the same patient data could be interpreted as either showing a significant clinical benefit or a potential harm, depending entirely on the mathematical approach selected by the investigators. This inconsistency highlights a substantial risk of advancing ineffective therapies into clinical practice based on statistical artifacts rather than true biological effects.

Risks to Evidence-Based Prescribing and Drug Development

The researchers assessed how different statistical approaches influence the risk of false-positive findings, which occur when a treatment is incorrectly identified as effective, and the statistical power to detect true treatment effects, or the ability of a study to identify a real clinical benefit. Among the 39 methods identified in the review, 38.9% (95% CI 24.8% to 55.1%) were at risk of increasing false-positive rates. This statistical instability is not merely a theoretical concern for researchers; it has direct clinical consequences. Increased false-positive rates potentially contribute to the erroneous advancement of ineffective treatments, leading clinicians to prescribe therapies that offer no genuine benefit to patients with amyotrophic lateral sclerosis. Furthermore, the statistical power of valid strategies varied widely, ranging from 17.9% to 78.2%, suggesting that even when a method is technically valid, it may be significantly underpowered to detect a meaningful clinical response. The study emphasizes that such variability in statistical methods can influence estimated treatment effects, potentially resulting in misleading conclusions and uncertainty regarding which therapies are truly efficacious. For the practicing physician, this methodological variability limits the interpretability and comparability of clinical trials, making it difficult to weigh the evidence from one study against another. This lack of standardization ultimately influences clinical decision-making and drug development by obscuring the true signal of therapeutic efficacy. To address these challenges, the authors suggest that establishing statistical consensus recommendations could improve the utility of disability scales, such as the revised ALS functional rating scale. By standardizing how data are analyzed, the medical community can ensure more reliable evidence, thereby accelerating progress toward effective therapies for neurodegenerative diseases.

References

1. Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology. 2020. doi:10.1038/s41582-020-00434-z

2. Benatar M, Wuu J, Andersen PM, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022. doi:10.1007/s13311-022-01237-4

3. Badri S, Mason J, Paganoni S, et al. Theme 09 - Clinical Trials and Trial Design. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2022. doi:10.1080/21678421.2022.2120685

4. Küffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nature Biotechnology. 2014. doi:10.1038/nbt.3051

5. Beeldman E, Raaphorst J, Twennaar MK, Visser MD, Schmand B, Haan RJD. The cognitive profile of ALS: a systematic review and meta-analysis update. Journal of Neurology Neurosurgery & Psychiatry. 2015. doi:10.1136/jnnp-2015-310734

6. Wit JD, Bakker LA, Groenestijn ACV, et al. Caregiver burden in amyotrophic lateral sclerosis: A systematic review. Palliative Medicine. 2017. doi:10.1177/0269216317709965

7. Weemering DN, Unnik JWJV, Genge A, Berg LHVD, Eijk RPAV. Heterogeneity in the Analysis of the ALSFRS-R in ALS Clinical Trials and its Effect on the Validity and Precision of Trial Conclusions.. Neurology. 2026. doi:10.1212/WNL.0000000000214937